Posts

Posted on

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III

NOVATO, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX053, an investigational mRNA therapy being evaluated for the treatment of Glycogen Storage Disease Type III (GSDIII). Enrollment in a Phase 1/2 study is expected to begin in the second half of 2021.

“FDA IND clearance paves the way for UX053 to enter the clinic as the first possible pharmacologic treatment option for patients with GSDIII,” said Camille L. Bedrosian, M.D., Chief Medical Officer of Ultragenyx. “UX053 is the most advanced of our investigational mRNA therapies, with multiple others in earlier preclinical development, and will be one of the first mRNA programs to enter clinical development for rare genetic diseases.”

Ultragenyx is developing UX053 and a number of other mRNA therapies in the preclinical stage for undisclosed indications. These mRNA therapies come out of a long-term collaboration with Arcturus Therapeutics, a clinical-stage messenger RNA medicines company.

Study Design

The two-part Phase 1/2 clinical trial will evaluate the safety, tolerability, and efficacy of UX053 in adults with GSDIII. Part 1 is open label and will enroll up to 12 patients who receive a single ascending dose of UX053. Part 2 is a randomized, double-blind, placebo-controlled multi-ascending study of 5 doses. It will enroll up to 16 patients across four cohorts randomized 3:1 to UX053 or placebo. In addition to safety, tolerability, and pharmacokinetics, study endpoints include clinician- and patient-reported outcomes, muscle strength, and biomarkers of liver, cardiac, and muscle health.

About Glycogen Storage Disease Type III

Our preclinical candidate UX053 is being developed for the treatment of GSDIII, a disease caused by a glycogen debranching enzyme (AGL) deficiency that results in glycogen accumulation in the liver and muscle. GSDIII can cause hepatomegaly, hypoglycemia, hyperlipidemia, some progressive liver cirrhosis, and skeletal and cardiac muscle disease. There are no approved treatment options for GSDIII and the current standard of care is a strict diet, including frequent doses of cornstarch, to reduce the risk of hypoglycemia. GSDIII affects more than 10,000 patients in the developed world.

About UX053

UX053 is an investigational mRNA-based biologic therapy encoding full-length, glycogen debranching enzyme encapsulated in a lipid nanoparticle (LNP) designed to provide the deficient protein in GSDIII.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at: www.ultragenyx.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx’s expectations and projections regarding its future operating results and financial performance, anticipated cost or expense reductions, the timing, progress and plans for its clinical programs and clinical studies, future regulatory interactions, and the components and timing of regulatory submissions are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration with third parties, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the effects from the COVID-19 pandemic on the company’s clinical activities, business and operating results, risks related to reliance on third party partners to conduct certain activities on the company’s behalf, uncertainty and potential delays related to clinical drug development, smaller than anticipated market opportunities for the company’s products and product candidates, manufacturing risks, competition from other therapies or products, and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the company’s future operating results and financial performance, the timing of clinical trial activities and reporting results from same, and the availability or commercial potential of Ultragenyx’s products and drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 12, 2021, and its subsequent periodic reports filed with the Securities and Exchange Commission.

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-660-0951



Posted on

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

MIAMI, March 08, 2021 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has engaged Morgan Stanley & Co. LLC as a financial advisor to assist the Company and its management in pursuing strategic alternatives regarding its legacy FC2 Female Condom® / FC2 Internal Condom business (FHC Business).

“With the last two consecutive quarters for our FHC Business having set all-time historical records in terms of net revenues and gross profit, and with the last three-year compound annual growth rates for the FHC Business’ net revenues and gross profit being 60% and 83%, respectively, we think this is an ideal time to consider strategic alternatives, including the possibility of monetizing this business, as we recently did with our PREBOOST business,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer. “Furthermore, with the potential for five registration clinical trials in calendar year 2021 — four for oncology indications and one for COVID-19 — it is clear that Veru has transformed itself into a premium, late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC Business is not as strong as it once was.”

Dr. Steiner added: “The FHC Business has been a great business for Veru. Fiscal year 2020 was a record year in terms of net revenues of $41 million and gross profit of $29 million, and Q1 fiscal year 2021 is already off on another record-setting pace. The cash flow generated by the FHC Business has allowed Veru to significantly advance its biopharmaceutical clinical programs. We are open to exploring the right kind of strategic transaction for the FHC Business with a view towards the best, long-term interests of Veru shareholders, which may include continuing to operate the FHC Business if we ultimately decide that is in our shareholders’ best interests.”

About the FHC Business

The FHC Business is Veru’s legacy business. Its commercial product is the FC2 Female Condom®/ FC2 Internal Condom (“FC2”), the only FDA approved female condom that provides dual protection against unintended pregnancy and the transmission of sexually transmitted infections. FC2 is sold commercially and in the public health sector both in the U.S. and globally. In the U.S., FC2 is available by prescription through multiple third-party telemedicine and internet pharmacy providers and retail pharmacies. In the global public health sector, the Company markets FC2 to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world. Over 650 million FC2 units have been sold globally in 159 countries. The FHC Business record growth has demonstrated a resiliency to the impact of the COVID-19 pandemic through a proven telemedicine prescription sales model. To learn more about the FC2 product, please visit www.verupharma.com


“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995:


There can be no assurance that any FHC Business strategic transaction will occur and there is no definitive timetable for such. The Company does not intend to make future announcements concerning this matter, unless or until it enters into a definitive agreement, or its board of directors determines to conclude the process, or it otherwise deems that further disclosure is appropriate or required.
The statements in this release that are not historical facts are “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements regarding
strategic alternatives with respect to, and the Company’s ability to potentially monetize
the Company’s legacy FHC Business, and the anticipated timeframe for clinical studies and FDA submissions of the Company’s biopharmaceutical drug candidates. Any forward-looking statements in this release are based upon the Company’s current plans and strategies and reflect the Company’s current assessment of the risks and uncertainties related to its business and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release because of new information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: the risk that the Company may not enter into a definitive agreement or otherwise proceed with any transaction regarding its FHC Business; costs, fees and expenses related to the process of exploring strategic alternatives with respect to the FHC Business
and the risk that the process may divert management’s attention from managing our business operations
; risks related to the development of the Company’s product portfolio, including clinical trials, regulatory approvals and time and cost to bring to market; potential delays in the timing of and results from clinical trials and studies, including potential delays in the recruitment of patients and their ability to effectively participate in such trials and studies due to COVID-19, and the risk that such results will not support marketing approval and commercialization; potential delays in the timing of any submission to the FDA and regulatory approval of products under development and the risk that
disruptions at the FDA caused by the COVID-19 pandemic may delay the review of submissions or approvals for new drugs
; the risk of a delay or failure in reaching agreement with the FDA on the design of a clinical trial or in obtaining authorization to commence a clinical trial; preclinical or clinical results or early data from clinical trials may not be replicated or continue to occur in additional trials or may not otherwise support further development in the specified product candidate or at all; our pursuit of a COVID-19 treatment candidate is at an early stage and we may be unable to develop a drug that successfully treats the virus in a timely manner, if at all; risks related to our commitment of financial resources and personnel to the development of a COVID-19 treatment which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties about the longevity and extent of COVID-19 as a global health concern and the possibility that as vaccines become widely distributed the need for new COVID-19 treatment candidates may be reduced or eliminated
;
government entities may take actions that directly or indirectly have the effect of limiting opportunities for VERU-111 as a COVID-19 treatment, including favoring other treatment alternatives or imposing price controls on COVID-19 treatments; the risk that the Company’s products may not be commercially successful; risks related to the impact of the COVID-19 pandemic on our business, the nature and extent of which is highly uncertain and unpredictable; risks relating to the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations, including our ability to secure timely grant or other funding to develop VERU-111 as a potential COVID-19 treatment; product demand and market acceptance; competition in the Company’s markets and therapeutic areas and the risk of new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; the risk that the Company will be affected by regulatory developments, including a reclassification of products; price erosion, both from competing products and increased government pricing pressures; manufacturing and quality control problems; compliance and regulatory matters, including costs and delays resulting from extensive governmental regulation, and effects of healthcare insurance and regulation, including reductions in reimbursement and coverage or reclassification of products; some of the Company’s products are in development and the Company may fail to successfully commercialize such products; risks related to intellectual property, including the uncertainty of obtaining patents, the effectiveness of the patents or other intellectual property protections and ability to enforce them against third parties, the uncertainty regarding patent coverages, the possibility of infringing a third party’s patents or other intellectual property rights, and licensing risks; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay, restructuring or substantial delayed payments; the risk that delays in orders or shipments under government tenders or the Company’s U.S. prescription business could cause significant quarter-to-quarter variations in the Company’s operating results and adversely affect its net revenues and gross profit; a governmental tender award indicates acceptance of the bidder’s price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum tender amount or award; penalties and/or debarment for failure to satisfy tender awards; the Company’s reliance on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector; risks related to concentration of accounts receivable with our largest customers and the collection of those receivables; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company’s production capacity, efficiency and supply constraints and interruptions, including potential disruption of production at the Company’s and third party manufacturing facilities and/or of the Company’s ability to timely supply product due to labor unrest or strikes, labor shortages, raw material shortages, physical damage to the Company’s and third party facilities, COVID-19 (including the impact of COVID-19 on suppliers of key raw materials), product testing, transportation delays or regulatory actions; risks related to the costs and other effects of litigation, including product liability claims; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company’s Form 10-K for the fiscal year ended September 30, 2020 and subsequent quarterly reports on Form 10-Q. These documents are available on the “SEC Filings” section of our website at

www.verupharma.com/investors

.

Investor Contact:
Sam Fisch  [email protected]
Director of Investor Relations

Corporate Development Contact:
Kevin Gilbert  [email protected]
EVP Corporate Development



Posted on

Danimer Scientific Announces Date for Fourth Quarter and Full Year 2020 Results

Danimer Scientific Announces Date for Fourth Quarter and Full Year 2020 Results

BAINBRIDGE, Ga.–(BUSINESS WIRE)–
Danimer Scientific (NYSE: DNMR) (“Danimer” or the “Company”), a leading developer and manufacturer of biodegradable materials, announced today that the Company will release its fourth quarter and full year 2020 financial results after the market closes on Monday, March 29, 2021. A webcast and conference call will be held that same day at 5:00 p.m. Eastern Time to review the Company’s fourth quarter and full year results, discuss recent events and conduct a question-and-answer session.

The live webcast of the conference call can be accessed on the Investor Relations section of the Company’s website at https://ir.danimerscientific.com/. For those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 1-877-407-9208 or 1-201-493-6784, respectively. Upon dialing in, please request to join the Danimer Scientific Fourth Quarter 2020 Earnings Conference Call. The archived webcast will be available for replay on the Company’s website after the call.

About Danimer Scientific

Danimer Scientific is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, our renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable. They return to nature instead of polluting our lands and waters. Our technology can be found in a vast array of plastic end products that people use every day. Applications for our biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. We now hold more than 150 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, visit www.DanimerScientific.com.

Forward‐Looking Statements

Please note that in this press release we may use words such as “appears,” “anticipates,” “believes,” “plans,” “expects,” “intends,” “future,” and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the overall level of consumer demand on our products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company’s customers; the Company’s ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to our products; the Company’s exposure to product liability or product warranty claims and other loss contingencies; disruptions and other impacts to the Company’s business, as a result of the COVID-19 global pandemic and government actions and restrictive measures implemented in response; stability of the Company’s manufacturing facilities and suppliers, as well as consumer demand for our products, in light of disease epidemics and health-related concerns such as the COVID-19 global pandemic; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company’s ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, our information systems; the ability of our information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; our ability to properly maintain, protect, repair or upgrade our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; our ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect the Company’s financial results is included from time to time in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release, and speak only as of the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.

Investors

[email protected]

Phone: 229-220-1103

Media

[email protected]

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Packaging Engineering Chemicals/Plastics Environment Manufacturing Other Manufacturing

MEDIA:

Posted on

HEICO Corporation Subsidiary Acquires Highly Successful Pyramid Semiconductor

HEICO Corporation Subsidiary Acquires Highly Successful Pyramid Semiconductor

MIAMI & SUNNYVALE, Calif.–(BUSINESS WIRE)–
HEICO Corporation (NYSE:HEI) (NYSE:HEI.A) today announced that its Electronic Technologies Group acquired the business, assets and certain liabilities of highly successful Pyramid Semiconductor LLC (“Pyramid”) from its founders for cash paid at closing. Additional transaction details were not disclosed.

HEICO stated that it expects the acquisition to be accretive to its earnings within a year following the closing.

Founded in 2003, Sunnyvale, CA-based Pyramid is a specialty semiconductor designer and manufacturer offering a well-developed line of processors, static random-access memory (SRAM), electronically erasable programmable read-only memory (EEPROM) and Logic products on a diverse array of military, space and medical platforms and are sold to numerous companies worldwide.

Joe Rothstein, Pyramid’s President, CEO and Co-Founder, along with Co-Founder and Vice President of Operations Douglas Beaubien, will continue with the business post-acquisition in their pre-acquisition roles. Further, HEICO stated that it does not expect any staff turnover to result from the acquisition and that the business will continue to operate from its existing Sunnyvale, CA facility.

The business will operate as a part of HEICO’s 3D PLUS USA subsidiary, which is also located in the Silicon Valley area. 3D PLUS USA supplies advanced high density 3D microelectronic products, and die stacking and wafer level stacking technologies for space and defense applications. 3D PLUS is known in the space and defense industries for its innovative products found on very demanding applications. Together, the two businesses will seek to provide customers additional products and capabilities.

Laurans A. Mendelson, HEICO’s Chairman and Chief Executive Officer, along with Victor H. Mendelson, HEICO’s Co-President and CEO of its Electronic Technologies Group, remarked, “We welcome Joe, Doug and the entire Pyramid team to the HEICO family. Pyramid is an entrepreneurial company known for producing excellent semiconductor products for hi-reliability applications and we look forward to having these capabilities within HEICO. We are also honored that Joe and Doug are entrusting us with the company they worked so hard to build over nearly 20 years.”

Joe Rothstein and Douglas Beaubien commented, “From our initial discussion with HEICO, we were excited to have our business join forces with HEICO and 3D PLUS to expand our product offering and market reach, while ensuring a good home for our company and our team. We believe this transaction will serve our staff, customers and all involved very well for the long-term.”

Timothee Dargnies, CEO of 3D PLUS USA, stated, “Pyramid and 3D PLUS USA both supply advanced technology products for the most stringent requirements to the most demanding customers and we are committed to new efforts to expand our offerings and to reach additional customers with advancing technology and excellent service.”

HEICO Corporation is engaged primarily in the design, production, servicing and distribution of products and services to certain niche segments of the aviation, defense, space, medical, telecommunications and electronics industries through its Hollywood, Florida-based Flight Support Group and its Miami, Florida-based Electronic Technologies Group. HEICO’s customers include a majority of the world’s airlines and overhaul shops, as well as numerous defense and space contractors and military agencies worldwide, in addition to medical, telecommunications and electronics equipment manufacturers. For more information about HEICO, please visit our website at www.heico.com.

Certain statements in this press release constitute forward-looking statements, which are subject to risks, uncertainties and contingencies. HEICO’s actual results may differ materially from those expressed in or implied by those forward-looking statements as a result of factors including: the severity, magnitude and duration of the COVID-19 Pandemic; HEICO’s liquidity and the amount and timing of cash generation; lower commercial air travel caused by the COVID-19 Pandemic and its aftermath, airline fleet changes or airline purchasing decisions, which could cause lower demand for our goods and services; product specification costs and requirements, which could cause an increase to our costs to complete contracts; governmental and regulatory demands, export policies and restrictions, reductions in defense, space or homeland security spending by U.S. and/or foreign customers or competition from existing and new competitors, which could reduce our sales; our ability to introduce new products and services at profitable pricing levels, which could reduce our sales or sales growth; product development or manufacturing difficulties, which could increase our product development and manufacturing costs and delay sales; our ability to make acquisitions and achieve operating synergies from acquired businesses; customer credit risk; interest, foreign currency exchange and income tax rates; economic conditions within and outside of the aviation, defense, space, medical, telecommunications and electronics industries, which could negatively impact our costs and revenues; and defense spending or budget cuts, which could reduce our defense-related revenue. Parties receiving this material are encouraged to review all of HEICO’s filings with the Securities and Exchange Commission, including, but not limited to filings on Form 10-K, Form 10-Q and Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.

Victor H. Mendelson (305) 374-1745 ext. 7590

Carlos L. Macau, Jr. (954) 987-4000 ext. 7570

KEYWORDS: United States North America California Florida

INDUSTRY KEYWORDS: Semiconductor Technology Satellite Aerospace Manufacturing Hardware

MEDIA:

Posted on

EXL Recognized as a Visionary in Gartner Magic Quadrant for Data and Analytics Services 2021

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a leading operations management and analytics company, today announced its placement as a Visionary in the Gartner Magic Quadrant for Data and Analytics Services 2021.

The report highlights several of EXL’s strengths, including its customizable analytics solutions combining domain expertise and data assets, partner-based models for co-developing innovative products with clients, and ability to create industry solutions with targeted value propositions.

“In today’s volatile and uncertain environment companies need to rely on data driven decisions to build and sustain market advantage. We at EXL are committed to help our clients leverage advanced analytics services including AI, machine learning, data scoring solutions, and cloud enablement to help them create market differentiation,” said Vivek Jetley, Executive Vice President and Head of Analytics, EXL. “I believe that being recognized as a Visionary, along with our distinction as the Gartner Peer Insights Customers’ Choice, demonstrates our strong data and analytics offerings, and we will continue to invest in these areas.”

Said Anita Mahon, Executive Vice President and Chief Growth & Strategy Officer, EXL, “Our commitment to being an indispensable partner to data-led businesses sits at the heart of our analytics capabilities. I am pleased to see our data investments and strategy be recognized by this placement, and look forward to driving further growth and innovations in this area.”

Additional strengths noted in the report included:

  • Services and solutions benefiting from strong key domain expertise and data assets curated from industry sources
  • Joint customer product R&D based on IP sharing, joint go-to-market strategies, and revenue sharing models
  • An acquisition strategy focusing on advanced analytics, AI, and data modernization fueled by the cloud

This latest placement follows EXL receiving the Customer’s Choice distinction in the report Gartner Peer Insights ‘Voice of the Customer’: Data and Analytics Service Providers. EXL was the only company to receive this recognition based on receiving over 50 reviews from customers, with clients offering statements such as how “EXL are fantastic partners, bringing innovation and business savvy to our engagements in addition to the analytical horsepower they employ.”

More information on this placement and the full report can be found by visiting this link.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About EXL

EXL (NASDAQ: EXLS) is a leading operations management and analytics company that helps our clients build and grow sustainable businesses. By orchestrating our domain expertise, data, analytics and digital technology, we look deeper to design and manage agile, customer-centric operating models to improve global operations, drive profitability, enhance customer satisfaction, increase data-driven insights, and manage risk and compliance. Headquartered in New York, EXL has approximately 31,900 professionals in locations throughout the United States, the United Kingdom, Europe, India, the Philippines, Colombia, Canada, Australia and South Africa. EXL serves customers in multiple industries including insurance, healthcare, banking and financial services, utilities, travel, transportation and logistics, media and retail, among others. For more information, visit www.exlservice.com.



Investor Relations
Steven N. Barlow
Vice President Investor Relations
212-624-5913
[email protected]

Media - US
Michael Sherrill
Vice President Marketing
646-419-0778
[email protected]

Media - Europe, India and APAC
Shailendra Singh
Vice President Corporate Communications
+91-98104-76075
[email protected]

Posted on

Ingersoll Rand Names Chris Miorin to Vice President of Investor Relations

Ingersoll Rand Names Chris Miorin to Vice President of Investor Relations

 

DAVIDSON, N.C.–(BUSINESS WIRE)–
Ingersoll Rand Inc. (NYSE: IR) appointed Chris Miorin today as its vice president of investor relations. Miorin replaces Vikram Kini in the role, who was appointed in June to chief financial officer.

Miorin assumes the role from his current one with the Ingersoll Rand Execution Excellence team where he has served as the vice president of corporate development since the merger of Gardner Denver and Ingersoll Rand’s industrial business in March 2020.

“Chris is a talented leader who demonstrates aptitude and excellent management capabilities with knowledge of our business strategy and operations,” said Kini. “He has played a critical role in accelerating Ingersoll Rand’s growth strategy, most recently with the acquisition of Tuthill Vacuum and Blower Systems and divestiture of the High Pressure Solutions segment. This experience will further build our program to engage more deeply with the investor community. I look forward to working alongside Chris as he continues to be an integral leader in executing our strategic plan to deliver both near and long-term value for our stockholders.”

A proud veteran of the United States Army, Miorin served as an infantry officer and Ranger from 2007-2012, including a deployment with the 25th Infantry Division in support of Operation Iraqi Freedom, leadership roles in The Old Guard at Arlington National Cemetery, and service as an aide to the President of the United States. After the military, he held roles as a controller with ExxonMobil, and investment banking associate with RBC Capital Markets and Simmons & Company International before joining Gardner Denver in June 2018 as the director of strategy and corporate development.

His community volunteerism is as impressive as his work experience. Miorin is passionate about education initiatives for underserved communities and supporting transitioning veterans. He served for two years as the service chair on the YPG Board of Directors with the Barbara Bush Houston Literacy Foundation and served three years as a board member and secretary of Combined Arms, an organization committed to veterans navigating the transition from military to civilian life.

Miorin has an MBA from Northwestern University and a Bachelor of Science degree from the United States Military Academy at West Point where he graduated with honors.

About Ingersoll Rand Inc.

Ingersoll Rand Inc. (NYSE:IR), driven by an entrepreneurial spirit and ownership mindset, is dedicated to helping make life better for our employees, customers and communities. Customers lean on us for our technology-driven excellence in mission-critical flow creation and industrial solutions across 40+ respected brands where our products and services excel in the most complex and harsh conditions. Our employees develop customers for life through their daily commitment to expertise, productivity and efficiency. For more information, visit www.IRCO.com.

Media:

Misty Zelent

[email protected]

Investor Relations:

Vikram Kini

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Engineering Chemicals/Plastics Oil/Gas Manufacturing Energy Other Manufacturing

MEDIA:

Logo
Logo
Posted on

Fogo de Chão Greets Spring With New Bone-In Ribeye and In-Season Market Table Offerings

New menu items include fresh salads at their peak, soup and dessert, all available for a limited time

DALLAS, March 08, 2021 (GLOBE NEWSWIRE) — Fogo de Chão, the internationally-renowned steakhouse that allows guests to discover “what’s next” at every turn, is celebrating the season of warmer weather with a new spring menu. From a flavorful, bone-in cut and Market Table salads to a house-made dessert and more, Fogo’s new spring selections are now available for a limited time as part of the Full Churrasco Experience at all restaurants nationwide.

“This time of year marks a period of renewal and fresh beginnings when we can bring in-season fruits, vegetables and fire-roasted additions to our menu for all of our guests to explore and enjoy,” said Barry McGowan, Chief Executive Officer of Fogo de Chão. “At Fogo, we strive to bring our guests joy while dining out through our Brazilian hospitality and continued innovation to enhance their experience.”  

Fogo’s innovative spring menu offerings include:

  • Bone-In Beef Ancho Ribeye: Aged for 21 days for more flavor, this ribeye is slow-roasted on the bone to preserve the rich flavors of bone-in steaks.
  • Whipped Ricotta with Crudité: Fresh ricotta cheese is topped with extra virgin olive oil, parsley, mint, roasted garlic and thyme, served alongside fresh vegetables.
  • Roasted Eggplant: Marinated with peppadew peppers, garlic, capers and fresh herbs, the roasted eggplant is then tossed with Extra Virgin Olive Oil and Balsamic Vinegar.
  • Apple Manchego Salad: Granny smith apples and manchego cheese are tossed with honey, lime zest and black mission figs.
  • Cucumber Salad: Fresh cucumber served with pickled onion and Brazilian vinaigrette.
  • Tomato Mozzarella Soup: Ripe tomatoes and fresh basil are blended with a touch of sour cream and Parmesan cheese, topped with buffalo mozzarella and Pão de Queijo croutons.
  • Passion Fruit Mousse: Rich passion fruit mousse is topped with tart passion fruit glaze and a puffed pastry crisp.

Each of the spring menu additions pairs perfectly with Fogo’s signature fire-roasted meats, including Picanha sirloin and tender lamb chops. Fogo’s a la carte seafood options like Chilled Lobster and Shrimp appetizer and indulgent cuts like a Wagyu New York Strip can be added to any dining experience for even more variety and decadence.

For more information about Fogo de Chão, its seasonal offerings or to make dining reservations, please visit http://www.fogo.com.


About Fogo de Chão


Fogo de Chão (fogo-dee-shown) is an internationally-renowned steakhouse that allows guests to discover what’s next at every turn. Founded in Southern Brazil in 1979, Fogo elevates the centuries-old cooking technique of churrasco – the art of roasting high-quality cuts of meat over an open flame – into a cultural dining experience of discovery. In addition to its Market Table and Feijoada Bar – which includes seasonal salads and soup, fresh vegetables, imported charcuterie and more – guests are served simply-seasoned meats that are butchered, fire-roasted and carved tableside by gaucho chefs. Guests can also indulge in dry-aged or premium Wagyu cuts, seafood a la carte, all-day happy hour featuring signature cocktails, and an award-winning South American wine list, as well as smaller, sharable plates in Bar Fogo. Fogo offers differentiated menus for all dayparts including lunch, dinner, weekend brunch and group dining, plus full-service catering and contactless takeout and delivery options.

Fogo has 55 locations across the globe, including 43 in the United States, six in Brazil, four in Mexico and two in the Middle East. Five additional U.S. locations, plus franchised restaurants in Mexico, are currently under development, including a flagship experience in Coral Gables, Fla., that will feature a Next Level cigar lounge and the Butchery.

For more information, visit Fogo.com, Facebook, Twitter and Instagram.

Media Contact:

[email protected] 

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ebea4dc5-75b6-4a3e-a848-d2146d9479a8

https://www.globenewswire.com/NewsRoom/AttachmentNg/557fe9c9-0526-45bd-9133-f1e20ea93765

https://www.globenewswire.com/NewsRoom/AttachmentNg/3383f55c-148f-4b3c-b37d-27f1c93a7100



Posted on

Industry Thought Leaders and Verint Experts to Spotlight the Future of Work and Experience Management in March

Industry Thought Leaders and Verint Experts to Spotlight the Future of Work and Experience Management in March

Opus Research Analysts Share Insights on How to Navigate the Latest Workforce Dynamics

MELVILLE, N.Y.–(BUSINESS WIRE)–Verint® (NASDAQ: VRNT), the Customer Engagement Company™, today announced the kickoff of two webinar series that focus on the future of work and the results of the latest Verint Experience Index™ (VXI) retail report.

How to Harness Key Future of Work Trends

Verint and Opus Research Webinar Series

Join this 3-part series of virtual panel discussions in March and April where Opus analysts and Verint experts share how organizations can build enduring customer relationships in light of ever-increasing, ever-shifting consumer demands.

March 11, 1 p.m.

In the first webinar, the panel will discuss the top workforce trends including: the growth of bots in the workplace; the increase in modalities that is causing data, functional and channel silos; and demand for real-time answers. Attendees can learn how to respond to these trends and prepare for the challenges they present.

Opus Research Moderators:

  • Dan Miller, lead analyst and founder
  • Derek Top, senior analyst and research director

Verint Panelists:

  • Tracy Malingo, global vice president and general manager, intelligent self-service
  • Heather Richards, vice president, product strategy, knowledge management
  • Dave Singer, vice president, GTM strategy, workforce engagement
  • Jen Snell, vice president, product strategy and marketing, intelligent self-service

VXI Retail 2020 Webinar Series

Join Verint experts as they break down the results of the latest Verint Experience Index™ (VXI) Retail report, based on a benchmark survey of consumer satisfaction with leading retailers and includes CSAT and NPS rankings. Consumers were surveyed in late November and early December 2020, with COVID-19 social-distancing guidelines in place and in the thick of the holiday shopping season. Verint’s Eric Head, vice president, experience leadership, Karly Szczepkowski, research analyst, and Ellen Schwartze, XM marketing programs manager will lead the discussions.

March 11, 1 p.m. ET

The 2020 Retail Customer Purchase Journey

Even in a pandemic, 46% of customers who made a purchase started in a store. And curbside pickup—which didn’t exist in 2019—beat out Buy Online, Pick Up In-Store (BOPIS) in fulfillment popularity. Learn how consumer behaviors have changed due to the pandemic including the growth of digital and its implications.

March 18, 1 p.m. ET

How Communication and Support Saved Retailers in 2020

In times of near-constant change, clear communication and competent support are still the foundation to instill trust in brands. While digital self-service can save millions of dollars, the human element in the contact center can’t be automated. Join the Verint panel of experts as they explore the differences in what customers want in digital versus support channels—and how businesses can benefit by understanding the nuance.

March 25, 1 p.m. ET

What’s Next? Retail CX Recommendations for 2021

New fulfillment methods such as curbside pickup, and a new wave of young, Gen-Z shoppers are changing the retail roadmap. Learn how Verint’s latest data can guide 2021 CX priorities—from quick website fixes to long-term vision for brands.

About Verint

Verint® (Nasdaq: VRNT) helps the world’s most iconic brands – including over 85 of the Fortune 100 companies – build enduring customer relationships by connecting work, data and experiences across the enterprise. The Verint Customer Engagement portfolio draws on the latest advancements in AI and analytics, an open cloud architecture, and The Science of Customer Engagement™ to help customers close the engagement capacity gap.

Verint. The Customer Engagement Company™. Learn more at Verint.com.

This press release contains “forward-looking statements,” including statements regarding expectations, predictions, views, opportunities, plans, strategies, beliefs, and statements of similar effect relating to Verint Systems Inc. These forward-looking statements are not guarantees of future performance and they are based on management’s expectations that involve a number of risks, uncertainties and assumptions, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. For a detailed discussion of these risk factors, see our Annual Report on Form 10-K for the fiscal year ended January 31, 2020, our Quarterly Report on Form 10Q for the quarter ended October 31, 2020, and other filings we make with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release and, except as required by law, Verint assumes no obligation to update or revise them or to provide reasons why actual results may differ.

VERINT, THE CUSTOMER ENGAGEMENT COMPANY, BOUNDLESS CUSTOMER ENGAGEMENT, THE ENGAGEMENT CAPACITY GAP and THE SCIENCE OF CUSTOMER ENGAGEMENT are trademarks of Verint Systems Inc. or its subsidiaries. Verint and other parties may also have trademark rights in other terms used herein.

Media Relations

Amy Curry

[email protected]

Investor Relations

Matthew Frankel

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Online Retail Data Management Retail Technology Other Retail Software

MEDIA:

Logo
Logo
Posted on

iRemedy Procures Supply of 500 Million More Low-Dead Space Syringes and Needles in Support of “Project Vaccinate”

STUART, Fla., March 08, 2021 (GLOBE NEWSWIRE) — The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that the Company has arranged for the procurement of an additional 500 million low-dead space syringes and needles in association with iRemedy’s “Project Vaccinate” initiative, created to support global demand for FDA-approved injection devices required for administration of COVID-19 vaccinations. This brings the Company’s total factory procurement of needles and syringes to over 1.8 billion, to date.

Working in close collaboration with its procurement partner Northfield to facilitate the order, iRemedy expects manufacturing of the additional half billion units to commence in May with delivery of the first shipments to the Company’s warehousing facilities in the U.S. within 30 days thereafter.

Max Kuperman, President of Northfield, stated, “With billions of doses of vaccine yet to be administered worldwide, we are very pleased to continue teaming with iRemedy to ensure that mass production of requisite needles and syringes is procured, and that the coordination of the complex logistical requirements associated with their sale and distribution is managed as swiftly and efficiently as possible.”  

iRemedy CEO Tony Paquin added, “Given the worldwide media attention that has been focused on mitigating unnecessary waste of valuable vaccine doses through the use of low-dead space syringes, this procurement effort has focused exclusively on securing reliable supply of this type of device. We are thrilled to have negotiated the manufacture and delivery of another half billion low-dead space syringes; and look forward to getting them into the hands of care organizations across the globe tasked with administering lifesaving vaccines.”  

For more information about Project Vaccinate, please contact Anthony Paquin directly at [email protected].

About The iRemedy Healthcare Companies

With 15 years in healthcare supply, iRemedy is a trusted and reliable partner for acquiring medical supplies and Personal Protective Equipment. We service over 5,000 healthcare provider, commercial and government clients nationwide. We guarantee access to verified supplies by sourcing directly from established manufacturers and distributors around the world. Our industry-leading technology and group purchasing power enable transparency and competition, driving consistently low pricing for our customers every day. iRemedy is headquartered in Stuart, Florida and has offices in New York, California and Washington, and distribution centers in Florida and Arizona. For more information, please visit www.iRemedy.com.

FOR MORE INFORMATION:

Keisha Graham                                
407-395-4283 | keisha@iremedy.com        

OR FOLLOW US ON:


Facebook



Twitter



LinkedIn



Instagram
                        



Posted on

Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the H.C. Wainwright Global Life Sciences Conference, a virtual event being held Tuesday, March 9th, and Wednesday, March 10th, 2021. Management is scheduled to present and will participate in virtual one-on-one meetings with institutional analysts and investors throughout the conference.

Management’s presentation will be available for on-demand viewing through the H.C. Wainwright conference portal beginning at 7:00 am ET on Tuesday, March 9th, 2021.

A webcast of Cassava Sciences’ presentation can be accessed under the ‘Investors’ tab at www.CassavaSciences.com and will be available for replay for 90 days following the event.

About Alzheimer’s Disease

Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.1 The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization.

About Simufilam, the Company’s Lead Drug Candidate

Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation. The underlying science for simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer’s Disease. Cassava Sciences is also developing an investigational diagnostic, called SavaDx, to detect Alzheimer’s disease with a simple blood test. Simufilam and SavaDx were both developed in-house. Both product candidates are substantially funded by peer-review research grant awards from the National Institutes of Health (NIH). Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third party.

About Cassava Sciences, Inc.

Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:

Eric Schoen, Chief Financial Officer
[email protected]
(512) 501-2450 


1

Alzheimer’s Disease International
,
Dementia Statistics
, available on-line
and accessed February 20, 2021
:

https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/